Hall Laurie J Trustee Increases Stake in Novartis AG (NVS)
Hall Laurie J Trustee lifted its holdings in Novartis AG (NYSE:NVS) by 0.3% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 16,713 shares of the company’s stock after purchasing an additional 50 shares during the period. Hall Laurie J Trustee’s holdings in Novartis AG were worth $1,395,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. City Holding Co. lifted its position in shares of Novartis AG by 4.6% in the 2nd quarter. City Holding Co. now owns 1,217 shares of the company’s stock worth $102,000 after purchasing an additional 54 shares during the period. WFG Advisors LP lifted its position in shares of Novartis AG by 38.1% in the 2nd quarter. WFG Advisors LP now owns 1,221 shares of the company’s stock worth $102,000 after purchasing an additional 337 shares during the period. Archford Capital Strategies LLC lifted its position in shares of Novartis AG by 72.3% in the 1st quarter. Archford Capital Strategies LLC now owns 1,480 shares of the company’s stock worth $110,000 after purchasing an additional 621 shares during the period. Kernodle & Katon Asset Management Group LLC lifted its position in shares of Novartis AG by 3.4% in the 1st quarter. Kernodle & Katon Asset Management Group LLC now owns 1,488 shares of the company’s stock worth $111,000 after purchasing an additional 49 shares during the period. Finally, Massey Quick & Co. LLC purchased a new stake in shares of Novartis AG in the 1st quarter worth approximately $119,000. 10.92% of the stock is owned by hedge funds and other institutional investors.
Several brokerages have recently weighed in on NVS. Zacks Investment Research raised shares of Novartis AG from a “hold” rating to a “buy” rating and set a $96.00 price target for the company in a research report on Tuesday, September 19th. Leerink Swann reaffirmed a “market perform” rating and issued a $83.00 price target on shares of Novartis AG in a research report on Thursday, June 22nd. Morgan Stanley raised shares of Novartis AG from an “underweight” rating to an “overweight” rating in a research report on Wednesday, July 26th. Credit Suisse Group cut shares of Novartis AG from a “neutral” rating to an “underperform” rating and set a $82.25 price target for the company. in a research report on Wednesday, July 5th. Finally, Cowen and Company set a $77.00 price target on shares of Novartis AG and gave the stock a “hold” rating in a research report on Tuesday, July 11th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and five have issued a buy rating to the stock. Novartis AG presently has an average rating of “Hold” and an average price target of $84.13.
Shares of Novartis AG (NYSE NVS) traded up 0.16% on Friday, reaching $86.13. 846,361 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $85.27 and a 200 day moving average of $81.85. The firm has a market capitalization of $201.79 billion, a P/E ratio of 31.45 and a beta of 0.73. Novartis AG has a one year low of $66.93 and a one year high of $86.90.
Novartis AG (NYSE:NVS) last issued its quarterly earnings results on Tuesday, July 18th. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.16 by $0.06. The company had revenue of $12.24 billion during the quarter, compared to the consensus estimate of $12.20 billion. Novartis AG had a net margin of 13.52% and a return on equity of 15.51%. The firm’s quarterly revenue was down 1.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.23 earnings per share. On average, equities research analysts predict that Novartis AG will post $4.75 EPS for the current year.
Novartis AG Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.